2002: August: Alzheimer’s Research Papers
Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward
Plant LD, Boyle JP, Thomas NM, Hipkins NJ, Benedikz E, Hooper NM, Henderson Z, Vaughan PF, Peers C, Cowburn RF, Pearson HA. Presenilin-1 mutations alter K+ currents in the human neuroblastoma cell line, SH-SY5Y. Neuroreport. 2002 Aug 27;13(12):1553-6.
Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig N, Lahiri DK, Tanzi RE, Bush AI, Giordano T, Gullans SR. An iron-responsive element type II in the 5' untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem. 2002 Aug 26;
Li L, von Bergen M, Mandelkow EM, Mandelkow E. Structure, stability, and aggregation of paired helical filaments from tau protein and FTDP-17 mutants probed by tryptophan scanning mutagenesis. J Biol Chem. 2002 Aug 26;
Helmuth L. New therapies. New Alzheimer's treatments that may ease the mind. Science. 2002 Aug 23;297(5585):1260-2.
Boussaha M, Hannequin D, Verpillat P, Brice A, Frebourg T, Campion D. Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease. Neurosci Lett. 2002 Aug 23;329(1):121. , ,
Apelt J, Lessig J, Schliebs R. beta-Amyloid-associated expression of intercellular adhesion molecule-1 in brain cortical tissue of transgenic Tg2576 mice. Neurosci Lett. 2002 Aug 23;329(1):111.
Chen Q, Schubert D. Presenilin-interacting proteins. Expert Rev Mol Med. 2002 Aug 22;4:1-18.
Liu L, Ikonen S, Heikkinen T, Heikkilä M, Puoliväli J, van Groen T, Tanila H. Effects of fimbria-fornix lesion and amyloid pathology on spatial learning and memory in transgenic APP+PS1 mice. Behav Brain Res. 2002 Aug 21;134(1-2):433.
Urani A, Romieu P, Roman F, Maurice T. Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice. Behav Brain Res. 2002 Aug 21;134(1-2):239.
Tornero D, Ce a V, Gonzalez Garcia C, Jordan J. [The role of the mitochondrial permeability transition pore in neurodegenerative processes] Rev Neurol. 2002 Aug 16;35(4):354-61.
Uryu S, Tokuhiro S, Murasugi T, Oda T. A novel compound, RS-1178, specifically inhibits neuronal cell death mediated by beta-amyloid-induced macrophage activation in vitro. Brain Res. 2002 Aug 16;946(2):298-306.
Lendon CL, Thaker U, Harris JM, McDonagh AM, Lambert JC, Chartier-Harlin MC, Iwatsubo T, Pickering-Brown SM, Mann DM. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci Lett. 2002 Aug 16;328(3):314-8. ,
Bagnoli S, Nacmias B, Tedde A, Guarnieri BM, Cellini E, Ciantelli M, Petruzzi C, Bartoli A, Ortenzi L, Serio A, Sorbi S. Cathepsin D polymorphism in Italian sporadic and familial Alzheimer's disease. Neurosci Lett. 2002 Aug 16;328(3):273-6. ,
Chung YH, Shin CM, Joo KM, Kim MJ, Cha CI. Region-specific alterations in insulin-like growth factor receptor type I in the cerebral cortex and hippocampus of aged rats. Brain Res. 2002 Aug 16;946(2):307-13.
Bi H, Sze CI. N-methyl-D-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer's disease. J Neurol Sci. 2002 Aug 15;200(1-2):11-8.
Terro F, Czech C, Esclaire F, Elyaman W, Yardin C, Baclet MC, Touchet N, Tremp G, Pradier L, Hugon J. Neurons overexpressing mutant presenilin-1 are more sensitive to apoptosis induced by endoplasmic reticulum-Golgi stress. J Neurosci Res. 2002 Aug 15;69(4):530-9.
Sakamoto S, Ishii K, Sasaki M, Hosaka K, Mori T, Matsui M, Hirono N, Mori E. Differences in cerebral metabolic impairment between early and late onset types of Alzheimer's disease. J Neurol Sci. 2002 Aug 15;200(1-2):27-32.
Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein J, Pierce W, Booze R, Markesbery W, Butterfield D. Proteomic identification of oxidatively modified proteins in alzheimer's disease brain. part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med. 2002 Aug 15;33(4):562.
Mueggler T, Sturchler-Pierrat C, Baumann D, Rausch M, Staufenbiel M, Rudin M. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J Neurosci. 2002 Aug 15;22(16):7218-24.
Delacourte A, Sergeant N, Champain D, Wattez A, Maurage CA, Lebert F, Pasquier F, David JP. Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology. 2002 Aug 13;59(3):398-407.
Jankowiak J. Depression may be another risk for Alzheimer's dementia: Your doctor can help. Neurology. 2002 Aug 13;59(3):E4-5.
Bower FL, McCullough CS, Pille BL. Synthesis of research findings regarding assessment/diagnosis of Alzheimer's disease--part I. Online J Knowl Synth Nurs. 2002 Aug 13;9:3.
Manabe T, Katayama T, Sato N, Kudo T, Matsuzaki S, Imaizumi K, Tohyama M. The cytosolic inclusion bodies that consist of splice variants that lack exon 5 of the presenilin-2 gene differ obviously from Hirano bodies observed in the brain from sporadic cases of Alzheimer's disease patients. Neurosci Lett. 2002 Aug 9;328(2):198-200.
Tang G, Zhang M, Xie H, Jiang S, Wang Z, Xu L, Hao Y, Lin D, Lan H, Wang Y, Chen L, Ren D. Alpha-2 macroglobulin I1000 V polymorphism in Chinese sporadic Alzheimer's disease and Parkinson's disease. Neurosci Lett. 2002 Aug 9;328(2):195-7. ,
Martin-Rehrmann MD, Cho HS, Rebeck GW. Lack of association of two lipoprotein lipase polymorphisms with Alzheimer's disease. Neurosci Lett. 2002 Aug 9;328(2):109-12. ,
Ayalasomayajula S, Kompella U. Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. Eur J Pharmacol. 2002 Aug 9;449(3):213.
Liou YJ, Hong CJ, Liu HC, Liu CY, Liu TY, Chen IC, Tsai SJ. No association between the neuronal nitric oxide synthase gene polymorphism and Alzheimer Disease. Am J Med Genet. 2002 Aug 8;114(6):687-8. ,
Bassett SS, Avramopoulos D, Fallin D. Evidence for parent of origin effect in late-onset Alzheimer disease. Am J Med Genet. 2002 Aug 8;114(6):679-86.
Beyer K, Lao JI, Gómez M, Riutort N, Latorre P, Mate JL, Ariza A. Identification of a protective allele against Alzheimer disease in the APOE gene promoter. Neuroreport. 2002 Aug 7;13(11):1403-1405. ,
Weeber EJ, Beffert U, Jones C, Christian JM, Forster E, Sweatt JD, Herz J. Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning. J Biol Chem. 2002 Aug 7;
Lashuel HA, Hartley DM, Balakhaneh D, Aggarwal A, Teichberg S, Callaway DJ. New class of inhibitors of amyloid-beta (Abeta ) fibril formation: Implications for the mechanism of pathogenesis in alzheimer's disease. J Biol Chem. 2002 Aug 6;
DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10843-10848.
Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10837-42.
Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Iivonen S, Mannermaa A, Tuomilehto J, Nissinen A, Soininen H. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002 Aug 6;137(3):149-55. ,
Infante J, Llorca J, Berciano J, Combarros O. No synergistic effect between -850 tumor necrosis factor-alpha promoter polymorphism and apolipoprotein E varepsilon4 allele in Alzheimer's disease. Neurosci Lett. 2002 Aug 2;328(1):71-3. ,
Desai P, DeKosky ST, Kamboh MI. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci Lett. 2002 Aug 2;328(1):9-12. ,
Yamaguchi Y, Matsuno T, Kawashima S. Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-beta 25-35 in the rat. Brain Res. 2002 Aug 2;945(2):259-65.
Helmuth L. Neuroscience. Long-awaited technique spots Alzheimer's toxin. Science. 2002 Aug 2;297(5582):752-3.
Bradley KM, O'Sullivan VT, Soper ND, Nagy Z, King EM, Smith AD, Shepstone BJ. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain. 2002 Aug;125(Pt 8):1772-81.
Laakso MP. Structural imaging in cognitive impairment and the dementias: an update. Curr Opin Neurol. 2002 Aug;15(4):415-21.
Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien JP, David S. Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci. 2002 Aug 1;22(15):6578-86.
Hoozemans JJ, Brückner MK, Rozemuller AJ, Veerhuis R, Eikelenboom P, Arendt T. Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J Neuropathol Exp Neurol. 2002 Aug;61(8):678-88.
Peng Q, Buz'Zard A, Lau B. Neuroprotective effect of garlic compounds in amyloid-b peptide-induced apoptosis in vitro. Med Sci Monit. 2002 Aug;8(8):BR328-37.
Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc. 2002 Aug;50(8):1431-8.
Fisher CM. Unexplained sudden amnesia. Arch Neurol. 2002 Aug;59(8):1310-3.
Salmon E. Functional brain imaging applications to differential diagnosis in the dementias. Curr Opin Neurol. 2002 Aug;15(4):439-44.
Liu N, Qiang W, Kuang X, Thuillier P, Lynn WS, Wong PK. The peroxisome proliferator phenylbutyric acid (PBA) protects astrocytes from ts1 MoMuLV-induced oxidative cell death. J Neurovirol. 2002 Aug;8(4):318-325.
Blass JP. Potential for a specific neuroradiologic diagnosis of Alzheimer's disease. J Nucl Med. 2002 Aug;43(8):1052-3.
Shi J, Perry G, Berridge MS, Aliev G, Siedlak SL, Smith MA, Lamanna JC, Friedland RP. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med. 2002 Aug;43(8):1044-51.
Butterfield D, Castegna A, Pocernich C, Drake J, Scapagnini G, Calabrese V. Nutritional approaches to combat oxidative stress in Alzheimer's disease. J Nutr Biochem. 2002 Aug;13(8):444.
Jacobs AR. Up-to-date on Alzheimer's disease. J Am Geriatr Soc. 2002 Aug;50(8):1449-50.
Brickman AM, Riba A, Bell K, Marder K, Albert M, Brandt J, Stern Y. Longitudinal assessment of patient dependence in Alzheimer disease. Arch Neurol. 2002 Aug;59(8):1304-8.
Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch Neurol. 2002 Aug 1;59(8):1258-63. ,
Wolfe MS, Esler WP, Das C. Continuing strategies for inhibiting Alzheimer's gamma-secretase. J Mol Neurosci. 2002 Aug-Oct;19(1-2):83-7.
McMahon BM, Stewart J, Fauq A, Younkin S, Younkin L, Richelson E. Using peptide nucleic acids as gene-expression modifiers to reduce beta-amyloid levels. J Mol Neurosci. 2002 Aug-Oct;19(1-2):71-6.
Kung MP, Hou C, Zhuang ZP, Skovronsky DM, Zhang B, Gur TL, Trojanowski JQ, Lee VM, Kung HF. Radioiodinated styrylbenzene derivatives as potential SPECT imaging agents for amyloid plaque detection in Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):7-10.
Jin LW, Hua DH, Shie FS, Maezawa I, Sopher B, Martin GM. Novel tricyclic pyrone compounds prevent intracellular APP C99-induced cell death. J Mol Neurosci. 2002 Aug-Oct;19(1-2):57-61.
Goto JJ, Tanzi RE. The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's A beta generation: development of a cell-based model system. J Mol Neurosci. 2002 Aug-Oct;19(1-2):37-41.
Di Rosa G, Odrijin T, Nixon RA, Arancio O. Calpain inhibitors: a treatment for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):135-41.
Yager D, Watson M, Healy B, Eckman EA, Eckman CB. Natural product extracts that reduce accumulation of the Alzheimer's amyloid beta peptide: selective reduction in A beta42. J Mol Neurosci. 2002 Aug-Oct;19(1-2):129-33.
Lazareno S, Popham A, Birdsall NJ. Towards a high-affinity allosteric enhancer at muscarinic M1 receptors. J Mol Neurosci. 2002 Aug-Oct;19(1-2):123-7.
Zeng L, Lu L, Muller M, Gouaux E, Zhou MM. Structure-based functional design of chemical ligands for AMPA-subtype glutamate receptors. J Mol Neurosci. 2002 Aug-Oct;19(1-2):113-6.
Zuo P, Luo P, Liu Y. Cholinergic receptor activity after quinolinic acid caused cerebral injury in rats. Chin Med J (Engl). 2002 Aug;115(8):1175-8.
Ono M, Kung M, Hou C, Kung H. Benzofuran derivatives as Abeta-aggregate-specific imaging agents for Alzheimer's disease. Nucl Med Biol. 2002 Aug;29(6):633.
Lockman PR, Allen DD. The transport of choline. Drug Dev Ind Pharm. 2002 Aug;28(7):749-71.
Luxenberg JS. Review: selegiline leads to a small short term improvement in cognition and activities of daily living in Alzheimer's disease. Evid Based Ment Health. 2002 Aug;5(3):88.
Onoue S, Endo K, Ohshima K, Yajima T, Kashimoto K. The neuropeptide PACAP attenuates beta-amyloid (1-42)-induced toxicity in PC12 cells. Peptides. 2002 Aug;23(8):1471.
Cui Y, Le Y, Zhang X, Gong W, Abe K, Sun R, Van Damme J, Proost P, Wang J. Up-regulation of FPR2, a chemotactic receptor for amyloid Beta 1-42 (abeta(42)), in murine microglial cells by TNFalpha. Neurobiol Dis. 2002 Aug;10(3):366.
Casley CS, Land JM, Sharpe MA, Clark JB, Duchen MR, Canevari L. Beta-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol Dis. 2002 Aug;10(3):258-67.
Janciauskiene S, Sun Y, Wright H. Interactions of abeta with endogenous anti-inflammatory agents: a basis for chronic neuroinflammation in Alzheimer's disease. Neurobiol Dis. 2002 Aug;10(3):187.
Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol. 2002 Aug;52(2):205-10.
Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002 Aug;52(2):168-74. ,
Villemagne P, Naidu S, Villemagne V, Yaster M, Wagner H, Harris J, Moser H, Johnston M, Dannals R, Wong D. Brain glucose metabolism in Rett Syndrome. Pediatr Neurol. 2002 Aug;27(2):117.
Kumar-Singh S, Cras P, Wang R, Kros JM, Van Swieten J, Lübke U, Ceuterick C, Serneels S, Vennekens K, Timmermans JP, Van Marck E, Martin JJ, van Duijn CM, van Broeckhoven C. Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric. Am J Pathol. 2002 Aug 1;161(2):507-20.
Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H, Blennow K, Andreasen N, Hofmann-Kiefer K, DeBernardis J, Kerkman D, McCulloch C, Kohnken R, Padberg F, Pirttilä T, Schapiro MB, Rapoport SI, Möller HJ, Davies P, Hampel H. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol. 2002 Aug;59(8):1267-72. ,
Rogers JT, Randall JD, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, Cahill CM, Moir R, Lahiri DK, Greig N, Sarang SS, Gullans SR. Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. J Mol Neurosci. 2002 Aug-Oct;19(1-2):77-82.
Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides. J Mol Neurosci. 2002 Aug-Oct;19(1-2):63-9.
Tun H, Marlow L, Pinnix I, Kinsey R, Sambamurti K. Lipid rafts play an important role in A beta biogenesis by regulating the beta-secretase pathway. J Mol Neurosci. 2002 Aug-Oct;19(1-2):31-5.
Perls T, Kunkel LM, Puca AA. The genetics of exceptional human longevity. J Mol Neurosci. 2002 Aug-Oct;19(1-2):233-8.
Sparks DL, Connor DJ, Browne P, Sabbagh MN, AD Cholesterol-Lowering Treatment Trial Team. Should the guidelines for monitoring serum cholesterol levels in the elderly be re-evaluated? J Mol Neurosci. 2002 Aug-Oct;19(1-2):209-12.
Strittmatter SM. Modulation of axonal regeneration in neurodegenerative disease: focus on Nogo. J Mol Neurosci. 2002 Aug-Oct;19(1-2):117-21.
Michaelis ML, Chen Y, Hill S, Reiff E, Georg G, Rice A, Audus K. Amyloid peptide toxicity and microtubule-stabilizing drugs. J Mol Neurosci. 2002 Aug-Oct;19(1-2):101-5.
Fillit HM, O'Connell AW, Refolo LM. Strategies for drug discovery for cognitive aging and Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):1-3.
Hedera P, Turner RS. Inherited dementias. Neurol Clin. 2002 Aug;20(3):779-808, vii.
Sabbagh MN, Lukas RJ, Sparks DL, Reid RT. The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. J Alzheimers Dis. 2002 Aug;4(4):317-25.
Shea TB, Lyons-Weiler J, Rogers E. Homocysteine, folate deprivation and Alzheimer neuropathology. J Alzheimers Dis. 2002 Aug;4(4):261-7.
Jellinger KA, Seppi K, Wenning GK. Lewy bodies in patients presenting clinically with Alzheimer disease. J Alzheimers Dis. 2002 Aug;4(4):327-8.
Grant P, Pant HC. Topographic regulation of kinase activity in Alzheimer's disease brains. J Alzheimers Dis. 2002 Aug;4(4):269-81.
Brunelle P, Rauk A. The radical model of Alzheimer's disease: Specific recognition of Gly29 and Gly33 by Met35 in a beta-sheet model of Abeta: An ONIOM study. J Alzheimers Dis. 2002 Aug;4(4):283-9.
Nandoe RD, Scheltens P, Eikelenboom P. Head trauma and Alzheimer's disease. J Alzheimers Dis. 2002 Aug;4(4):303-8.
Kanemaru K, Yamanouchi H. Assessment of CSF homovanillic acid levels distinguishes dementia with Lewy bodies from Alzheimer's disease. J Neurol. 2002 Aug;249(8):1125-6.
Bazan NG, Colangelo V, Lukiw WJ. Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:197-210.
Rafael H, Fernández E, Ayulo V. Hypertension directly relates to Alzheimer disease. J Alzheimers Dis. 2002 Aug;4(4):329-30;
Weisburger JH. Lifestyle, health and disease prevention: the underlying mechanisms. Eur J Cancer Prev. 2002 Aug;11 Suppl 2:S1-7.
Back-Madruga C, Boone K, Briere J, Cummings J, McPherson S, Fairbanks L, Thompson E. Functional ability in executive variant Alzheimer's disease and typical Alzheimer's disease. Clin Neuropsychol. 2002 Aug;16(3):331-40.
Yamashita M, Yamamoto T. [Coexistence of motor neuron disease with dementia and Alzheimer's disease] Rinsho Shinkeigaku. 2002 Aug;42(8):771; discussion 772.
Morrison-Bogorad M. Alzheimer's disease. Hope for the future. Caring. 2002 Aug;21(8):12-5.
Levin ED, Rezvani AH. Nicotinic treatment for cognitive dysfunction. Curr Drug Target CNS Neurol Disord. 2002 Aug;1(4):423-31.
Graham AJ, Martin-Ruiz CM, Teaktong T, Ray MA, Court JA. Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders. Curr Drug Target CNS Neurol Disord. 2002 Aug;1(4):387-97.
O'Neill MJ, Murray TK, Lakics V, Visanji NP, Duty S. The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration. Curr Drug Target CNS Neurol Disord. 2002 Aug 1;1(4):399-411.
Rainville C, Amieva H, Lafont S, Dartigues JF, Orgogozo JM, Fabrigoule C. Executive function deficits in patients with dementia of the Alzheimer's type. A study with a Tower of London task. Arch Clin Neuropsychol. 2002 Aug;17(6):513-30.
Bolton JL. Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens. Toxicology. 2002 Aug 1;177(1):55-65.
Nobili F, Vitali P, Canfora M, Girtler N, De Leo C, Mariani G, Pupi A, Rodriguez G. Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol. 2002 Aug;113(8):1241-8.
LeVine H. 4,4(')-Dianilino-1,1(')-binaphthyl-5,5(')-disulfonate: report on non-beta-sheet conformers of Alzheimer's peptide beta(1-40). Arch Biochem Biophys. 2002 Aug 1;404(1):106-15.
Miyazaki I, Asanuma M, Higashi Y, Sogawa CA, Tanaka K, Ogawa N. Age-related changes in expression of metallothionein-III in rat brain. Neurosci Res. 2002 Aug;43(4):323-33.
Goto S, Takahashi A, Kamisango K, Matsubara K. Single-nucleotide polymorphism analysis by hybridization protection assay on solid support. Anal Biochem. 2002 Aug 1;307(1):25-32.
Trenkwalder P. Potential for antihypertensive treatment with an AT(1)-receptor blocker to reduce dementia in the elderly. J Hum Hypertens. 2002 Aug;16 Suppl 3:S71-5.
Uylings HB, de Brabander JM. Neuronal changes in normal human aging and Alzheimer's disease. Brain Cogn. 2002 Aug;49(3):268-76.
Normann HK, Norberg A, Asplund K. Confirmation and lucidity during conversations with a woman with severe dementia. J Adv Nurs. 2002 Aug;39(4):370-6.
Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL, Trent HCV Study Group. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology. 2002 Aug;36(2):456-63.
Tsuboi Y, Kakimoto K, Akatsu H, Daikuhara Y, Yamada T. Hepatocyte growth factor in cerebrospinal fluid in neurologic disease. Acta Neurol Scand. 2002 Aug;106(2):99-103.
Tan J, Town T, Mullan M. CD40-CD40L interaction in Alzheimer's disease. Curr Opin Pharmacol. 2002 Aug;2(4):445-51.
Dei R, Takeda A, Niwa H, Li M, Nakagomi Y, Watanabe M, Inagaki T, Washimi Y, Yasuda Y, Horie K, Miyata T, Sobue G. Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease. Acta Neuropathol (Berl). 2002 Aug;104(2):113-22.
Chertkow H. Mild cognitive impairment. Curr Opin Neurol. 2002 Aug;15(4):401-407.
Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002 Aug 1;22(15):6331-5.
Ingles JL, Wentzel C, Fisk JD, Rockwood K. Neuropsychological predictors of incident dementia in patients with vascular cognitive impairment, without dementia. Stroke. 2002 Aug;33(8):1999-2002.
Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, Miklossy J. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke. 2002 Aug;33(8):1986-92.
Caricasole A, Bruno V, Cappuccio I, Melchiorri D, Copani A, Nicoletti F. A novel rat gene encoding a Humanin-like peptide endowed with broad neuroprotective activity. FASEB J. 2002 Aug;16(10):1331-3.
Beher D, Wrigley JD, Owens AP, Shearman MS. Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretase activity. J Neurochem. 2002 Aug;82(3):563-75.
Griffin WS, Mrak RE. Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J Leukoc Biol. 2002 Aug;72(2):233-8.
Eldridge LL, Masterman D, Knowlton BJ. Intact implicit habit learning in Alzheimer's disease. Behav Neurosci. 2002 Aug;116(4):722-6.
Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol. 2002 Aug;15(4):445-50.
Shamas-Ud-Din S. Genetics of Down's syndrome and Alzheimer's disease. Br J Psychiatry. 2002 Aug;181(2):167-8.
Albert KA, Hemmings HC, Adamo AI, Potkin SG, Akbarian S, Sandman CA, Cotman CW, Bunney WE, Greengard P. Evidence for Decreased DARPP-32 in the Prefrontal Cortex of Patients With Schizophrenia. Arch Gen Psychiatry. 2002 Aug;59(8):705-12.
Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, Livingston G, Ince P, McKeith IG, Katona CL. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):134-40.
Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):126-133.
Town T, Zolton J, Shaffner R, Schnell B, Crescentini R, Wu Y, Zeng J, DelleDonne A, Obregon D, Tan J, Mullan M. p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J Neurosci Res. 2002 Aug 1;69(3):362-372.
Ushijima Y, Okuyama C, Mori S, Nakamura T, Kubota T, Nishimura T. Relationship between cognitive function and regional cerebral blood flow inAlzheimer's disease. Nucl Med Commun. 2002 Aug;23(8):779-84.
Balbach JJ, Petkova AT, Oyler NA, Antzutkin ON, Gordon DJ, Meredith SC, Tycko R. Supramolecular Structure in Full-Length Alzheimer's beta-Amyloid Fibrils: Evidence for a Parallel beta-Sheet Organization from Solid-State Nuclear Magnetic Resonance. Biophys J. 2002 Aug;83(2):1205-16.
Uberti D, Carsana T, Bernardi E, Rodella L, Grigolato P, Lanni C, Racchi M, Govoni S, Memo M. Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. J Cell Sci. 2002 Aug 1;115(Pt 15):3131-8.
Levine B, Cabeza R, McIntosh AR, Black SE, Grady CL, Stuss DT. Functional reorganisation of memory after traumatic brain injury: a study with H(2)(15)0 positron emission tomography. J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):173-181.
Seiler N. Ammonia and Alzheimer's disease. Neurochem Int. 2002 Aug-Sep;41(2-3):189-207.
Mahmood I. Selegiline transdermal system Somerset. Curr Opin Investig Drugs. 2002 Aug;3(8):1230-3.
Schreiner AS, Morimoto T. Factor structure of the Cornell Scale for Depression in Dementia among Japanese poststroke patients. Int J Geriatr Psychiatry. 2002 Aug;17(8):715-22.
Heinik J, Solomesh I, Raikher B, Lin R. Can clock drawing test help to differentiate between dementia of the Alzheimer's type and vascular dementia? A preliminary study. Int J Geriatr Psychiatry. 2002 Aug;17(8):699-703.
Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jäckel S, Wei X, Buerger K, Höft C, Hemmer B, Möller HJ, Farlow M, Oertel WH, Sommer N, Du Y. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol. 2002 Aug;52(2):253-6. ,
Sheline CT, Choi EH, Kim-Han JS, Dugan LL, Choi DW. Cofactors of mitochondrial enzymes attenuate copper-induced death in vitro and in vivo. Ann Neurol. 2002 Aug;52(2):195-204.
Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ, Kaye JA, Morrow JD. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol. 2002 Aug;52(2):175-9. ,
Howell WM, Brookes AJ. Evaluation of multiple presenilin 2 SNPs for association with early-onset sporadic Alzheimer disease. Am J Med Genet. 2002 Aug 1;111(2):157-63. ,
Benvenuto J, Jin Y, Casale M, Lynch G, Granger R. Identification of diagnostic evoked response potential segments in Alzheimer's disease. Exp Neurol. 2002 Aug;176(2):269-76.
Biegon A, Alvarado M, Budinger TF, Grossman R, Hensley K, West MS, Kotake Y, Ono M, Floyd RA. Region-selective effects of neuroinflammation and antioxidant treatment on peripheral benzodiazepine receptors and NMDA receptors in the rat brain. J Neurochem. 2002 Aug;82(4):924-34.
Namekata K, Nishimura N, Kimura H. Presenilin-binding protein forms aggresomes in monkey kidney COS-7 cells. J Neurochem. 2002 Aug;82(4):819-27.
Matsuda A, Kazui H, Hirono N, Mori E. [Validity of the Japanese version of Rivermead Behavioural Memory Test for evaluation of everyday memory function in patients with mild Alzheimer's disease] No To Shinkei. 2002 Aug;54(8):673-8.
Moss SE, Polignano E, White CL, Minichiello MD, Sunderland T. Reminiscence group activities and discourse interaction in Alzheimer's disease. J Gerontol Nurs. 2002 Aug;28(8):36-44.
Bodemer W, Kaup FJ. [Basic research on BSE transmission to people] Dtsch Tierarztl Wochenschr. 2002 Aug;109(8):338-41.
Goethals I, Van De Wiele C, Slosman D, Dierckx R. Brain SPET perfusion in early Alzheimer's disease: where to look? Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):975-8.
Tamir S, Izrael S, Vaya J. The effect of oxidative stress on ERalpha and ERbeta expression. J Steroid Biochem Mol Biol. 2002 Aug;81(4-5):327-32.
Kamino K, Tanaka T, Kida T, Ohkochi M, Tanii H, Kudo T, Takeda M. [The role of lipid metabolism in Alzheimer's disease] Nihon Shinkei Seishin Yakurigaku Zasshi. 2002 Aug;22(4):103-10.
Rochette MJ, Murphy MP. Gamma-secretase: substrates and inhibitors. Mol Neurobiol. 2002 Aug;26(1):81-95.
Nakamura Y. Regulating factors for microglial activation. Biol Pharm Bull. 2002 Aug;25(8):945-53.
Vicioso BA. Dementia: when is it not Alzheimer disease? Am J Med Sci. 2002 Aug;324(2):84-95.
Wisniewski T, Brown DR, Sigurdsson EM. Therapeutics in Alzheimer's and prion diseases. Biochem Soc Trans. 2002 Aug;30(4):574-8.
Eberling JL. Oestrogen has neuroprotective effects and may reduce the risk of Alzheimer's disease. Expert Opin Biol Ther. 2002 Aug;2(6):647-57.
Noonan CW, Reif JS, Burch JB, Ichinose TY, Yost MG, Magnusson K. Relationship between amyloid beta protein and melatonin metabolite in a study of electric utility workers. J Occup Environ Med. 2002 Aug;44(8):769-75.
Lyketsos C, Olin J. Depression in Alzheimer's disease: overview and treatment. Biol Psychiatry. 2002 Aug 1;52(3):243.
Alexopoulos G, Borson S, Cuthbert B, Devanand D, Mulsant B, Olin J, Oslin D. Assessment of late life depression. Biol Psychiatry. 2002 Aug 1;52(3):164.
Muñoz Negrete FJ, Rebolleda G. [Automated perimetry and neuro-ophthalmology. Topographic correlation] Arch Soc Esp Oftalmol. 2002 Aug;77(8):413-28.
Ito T, Yamadera H. [The efficacy of donepezil in Alzheimer's disease] J Nippon Med Sch. 2002 Aug;69(4):379-82.
Meyer JS, Xu G, Thornby J, Chowdhury MH, Quach M. Is mild cognitive impairment prodromal for vascular dementia like Alzheimer's disease? Stroke. 2002 Aug;33(8):1981-5.
Hauss-Wegrzyniak B, Lynch MA, Vraniak PD, Wenk GL. Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses. Exp Neurol. 2002 Aug;176(2):336-41.
Boutaud O, Ou JJ, Chaurand P, Caprioli RM, Montine TJ, Oates JA. Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1-42 oligomers. J Neurochem. 2002 Aug 1;82(4):1003-6.
Kinoshita A, Whelan CM, Smith CJ, Berezovska O, Hyman BT. Direct visualization of the gamma secretase-generated carboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus. J Neurochem. 2002 Aug 1;82(4):839-47.
Han X, M Holtzman D, McKeel DW, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem. 2002 Aug;82(4):809-18. ,
Chidiac C, Braun E. [Atherosclerosis, multiple sclerosis, and Alzheimer's disease: what role for Herpesviridae?] Pathol Biol (Paris). 2002 Aug;50(7):463-8.
Holecek V, Racek J, Trefil L, Rokyta R. [Free radicals and antioxidants in cerebrospinal fluid in central nervous system diseases] Cesk Fysiol. 2002 Aug;51(3):129-32.
Rasmusson AM, Shi L, Duman R. Downregulation of BDNF mRNA in the Hippocampal Dentate Gyrus after Re-exposure to Cues Previously Associated with Footshock. Neuropsychopharmacology. 2002 Aug;27(2):133-42.
Zhang XJ, Yang L, Zhao Q, Caen JP, He HY, Jin QH, Guo LH, Alemany M, Zhang LY, Shi YF. Induction of acetylcholinesterase expression during apoptosis in various cell types. Cell Death Differ. 2002 Aug;9(8):790-800.
Blount PJ, Nguyen CD, McDeavitt JT. Clinical use of cholinomimetic agents: a review. J Head Trauma Rehabil. 2002 Aug;17(4):314-21.
Nobili F, Koulibaly M, Vitali P, Migneco O, Mariani G, Ebmeier K, Pupi A, Robert PH, Rodriguez G, Darcourt J. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med. 2002 Aug;43(8):983-90.
Dodart JC, Mathis C, Bales KR, Paul SM. Does my mouse have Alzheimer's disease? Genes Brain Behav. 2002 Aug;1(3):142-55.
Weksler ME, Goodhardt M. Do age-associated changes in 'physiologic' autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease? Exp Gerontol. 2002 Aug-Sep;37(8-9):971-9.
Iqbal K, Alonso Adel C, El-Akkad E, Gong CX, Haque N, Khatoon S, Pei JJ, Tsujio I, Wang JZ, Grundke-Iqbal I. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J Mol Neurosci. 2002 Aug-Oct;19(1-2):95-9.
Yu J, Bakhos L, Chang L, Holterman MJ, Klein WL, Venton DL. Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers. J Mol Neurosci. 2002 Aug-Oct;19(1-2):51-5.
Kisilevsky R, Szarek WA. Novel glycosaminoglycan precursors as anti-amyloid agents part II. J Mol Neurosci. 2002 Aug-Oct;19(1-2):45-50.
Bowirrat A, Friedland RP, Farrer L, Baldwin C, Korczyn A. Genetic and environmental risk factors for Alzheimer's disease in Israeli Arabs. J Mol Neurosci. 2002 Aug-Oct;19(1-2):239-45.
Grundman M, Sencakova D, Jack CR, Petersen RC, Kim HT, Schultz A, Weiner MF, DeCarli C, DeKosky ST, van Dyck C, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative Study. Brain MRI hippocampal volume and prediction of clinical status in a mild cognitive impairment trial. J Mol Neurosci. 2002 Aug-Oct;19(1-2):23-7.
Bendheim PE, Poeggeler B, Neria E, Ziv V, Pappolla MA, Chain DG. Development of indole-3-propionic acid (OXIGON) for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):213-7.
Tuszynski MH, Thal L, U HS, Pay MM, Blesch A, Conner J, Vahlsing HL. Nerve growth factor gene therapy for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):207.
Belanoff JK, Jurik J, Schatzberg LD, DeBattista C, Schatzberg AF. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J Mol Neurosci. 2002 Aug-Oct;19(1-2):201-6.
Messer WS. The utility of muscarinic agonists in the treatment of Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):187-93.
Small GW. Brain-imaging surrogate markers for detection and prevention of age-related memory loss. J Mol Neurosci. 2002 Aug-Oct;19(1-2):17-21.
Levin-Allerhand JA, Smith JD. Ovariectomy of young mutant amyloid precursor protein transgenic mice leads to increased mortality. J Mol Neurosci. 2002 Aug-Oct;19(1-2):163-6.
Petanceska SS, DeRosa S, Olm V, Diaz N, Sharma A, Thomas-Bryant T, Duff K, Pappolla M, Refolo LM. Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci. 2002 Aug-Oct;19(1-2):155-61.
Fisher A, Brandeis R, Bar-Ner RH, Kliger-Spatz M, Natan N, Sonego H, Marcovitch I, Pittel Z. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53.
Wang Y, Klunk WE, Huang GF, Debnath ML, Holt DP, Mathis CA. Synthesis and evaluation of 2-(3'-iodo-4'-aminophenyl)-6-hydroxybenzothiazole for in vivo quantitation of amyloid deposits in Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):11-6.
No comments:
Post a Comment